Sovaldi and Killer cells in hepatitis C Virus Infected patients in Egypt during infection with Covid 19

In December 2019, Wuhan, China, reported a new case of coronavirus-induced pneumonia. The severe acute respiratory syndrome coronavirus was the name given to this virus upon its identification. The World Health Organization has designated coronavirus disease in 2019 as an abbreviation COVID-19.The treatment of chronic hepatitis C virus has revolutionized with the development of medications like Sovaldi that directly act on particular hepatitis C virus target structures. Almost all patients, regardless of their comorbidity, can now receive therapeutic treatment. One of the main cell types reacting to interferon is natural killer cells. Therefore, it seems sense to believe that natural killer cells will play a role in the body's reaction to interferon, an antiviral medication used to treat chronic hepatitis C infection. Natural killer cells recognize infected hepatoma cells with hepatitis C virus after interferon stimulation in a DNAX Accessory Molecule-1 dependent manner. The purpose of this study was to assess the relation between Covid-19, Natural killer cells (CD16, CD56) and Sovaldi as anti-viral which used as a treatment of hepatitis C virus. Methods we analyzed data from 80 patients and 40 persons as a control recruited in hospital. We calculated the percentage of responders to treatment and effect of treatment. Results we found that the frequency of CD56 and CD16 in responders whom infected with covid 19 is high while in responders whom not infected with covid 19 and in non-responders was normal. Conclusions The study has demonstrated that Sovaldi improve the response of patients to covid 19 treatments.